Clinical Study of YQ1 Plus Cisplatin-based Chemotherapy in Advanced NSCLC EGFR Wild Type
Status:
Unknown status
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
This randomized pilot phase II trial studies the effect of YQ1, a herbal medicine, with
cisplatin-based chemotherapy on gut microbiota and immune response in patients with EGFR/ALK
wild type non-small cell lung cancer, stage IIIB-IV.